tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Syntara Limited Schedules Investor Webinar Amidst Quarterly Update

Story Highlights
  • Syntara Limited is a clinical-stage drug company focusing on blood cancers and fibrosis.
  • Syntara announced a webinar following a delay in filing its quarterly cash flow report.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Syntara Limited Schedules Investor Webinar Amidst Quarterly Update

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Pharmaxis Ltd ( (AU:SNT) ) has shared an update.

Syntara Limited announced an investor webinar to discuss its quarterly update and recent developments, including the filing of its Appendix 4C Quarterly Cash Flow Report after an administrative delay. The company’s securities were temporarily suspended due to the delay, but are expected to resume trading shortly. This announcement highlights Syntara’s ongoing efforts in drug development, particularly with its lead candidate amsulostat for myelofibrosis, and its strategic focus on advancing treatments for fibrotic and inflammatory diseases. The webinar aims to engage shareholders and investors, providing insights into the company’s progress and future plans.

The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.

More about Pharmaxis Ltd

Syntara Limited is a clinical-stage drug development company specializing in targeting extracellular matrix dysfunction. Utilizing expertise in amine oxidase chemistry, Syntara develops novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, amsulostat, is being developed for myelofibrosis and has received Fast Track Designation from the FDA. The company is also advancing other drug candidates for various fibrotic and inflammatory diseases, including kidney fibrosis and neurodegenerative diseases like Parkinson’s. Syntara is listed on the Australian Securities Exchange and is based in Sydney, Australia.

Average Trading Volume: 9,771,429

Technical Sentiment Signal: Sell

Current Market Cap: A$97.56M

For an in-depth examination of SNT stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1